As it shifts strategic direction…
As it shifts strategic direction to prioritize its recently acquired [...]
After a year marked by dramatic…
After a year marked by dramatic ups and downs, William [...]
Zealand Pharma may be gearing up…
Zealand Pharma may be gearing up for a high-stakes year [...]
Thursday, the FDA greenlighted…
Thursday, the FDA greenlighted Uplizna to treat generalized myasthenia gravis [...]
With an increase in the…
With an increase in the antimicrobial resistance to therapies for [...]
A key late-stage trial of Arcus…
A key late-stage trial of Arcus Biosciences and Gilead’s anti-TIGIT [...]
Cycle Pharmaceuticals is circling…
Cycle Pharmaceuticals is circling up Applied Therapeutics, acquiring the rare [...]
Pfizer is paying top dollar for a…
Pfizer is paying top dollar for a GLP-1 candidate from [...]
The long-planned legislation…
The long-planned legislation contains “encouraging steps” but is overall “not [...]
After winning an approval decades…
After winning an approval decades in the making last year—and [...]